M

Madrigal Pharmaceuticals
D

MDGL

432.67
USD
1.50
(0.35%)
مغلق
حجم التداول
12,385
الربح لكل سهم
-12
العائد الربحي
-
P/E
-34
حجم السوق
9,643,787,687
أصول ذات صلة
EXEL
EXEL
0.520
(1.39%)
37.900 USD
INSM
INSM
2.550
(1.79%)
145.140 USD
K
KPTI
-0.16000
(-2.37%)
6.60000 USD
المزيد
الأخبار المقالات

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.